Nyxoah SA (EBR:NYXH)
Belgium · Delayed Price · Currency is EUR 5.29
-0.10 (-1.86%)
Last updated: Aug 29, 2025, 2:49 PM CET
Nyxoah Company Description
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA).
The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA
| Country | Belgium |
| Founded | 2009 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 184 |
| CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 1 022 23 55 |
| Website | nyxoah.com |
Stock Details
| Ticker Symbol | NYXH |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0974358906 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Olivier Taelman | Chief Executive Officer and Executive Director |
| Robert Taub MBA | Co-Founder and Chairman |
| John Landry | Chief Financial Officer |
| Bruno Onkelinx | Chief Technical Officer |
| Mikaela Kirkwood | Corporate Communication and Investor Relations Manager |
| An Moonen | General Counsel |
| Maggie McGowan | Chief Human Resources Officer |
| Remi Renard | Chief of Staff |
| Jeyakumar Subbaroyan | Chief Clinical Officer |
| Francis S. Kim | Chief Regulatory and Quality Officer |